Japan Patent Granted for bioAffinity's AI Lung Cancer Test
bioAffinity Technologies received a notice of allowance for a Japanese patent covering its CyPath Lung test, expanding its intellectual property and protecting the noninvasive lung cancer diagnostic in the Asian market.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed